Headache, convulsions, chest pain … are the clinical symptoms that can be seen in Covid-19 vaccinated people with complications of blood clotting, thrombocytopenia. This is a rare serious event.
The Ministry of Health has just issued Decision No. 1966 / QD-BYT on guiding the diagnosis and treatment of thrombocytopenia and thrombotic syndrome after vaccination. Covid-19 . Accordingly, thromboembolism accompanied by thrombocytopenia following the Covid-19 vaccination of AstraZeneca and Johnson & Johnson has been documented in the reports of pharmacies and organizations that monitor the safety of vaccines. -xin in many countries.
Covid-19 vaccination for medical staff – Photo: Minh Anh The World Health Organization (WHO) has requested vigilance, monitoring, early detection and timely management of rare human events after Covid-19 vaccination with suspected immune thrombocytopenia. , scattered blood clots in the lumen, cerebral venous thrombosis. The rate of thrombosis after AstraZeneca vaccination is 4.6 / 1 million doses of the first injection, Pfizer-BioNTech Covid-19 vaccine is 0.2 / 1 million doses of the first injection. Thrombosis after AstraZeneca vaccination is mainly seen in women, in Germany there are 29 out of 31 women with thrombosis are women. The rate of blood clotting after AstraZeneca vaccination in young people is higher than in the elderly, especially in the age group 20-29. After vaccination AstraZeneca, the phenomenon of blood clotting seems less likely to occur in people over 60 years old, only about 0.2 / 1 million doses of the first injection. Complications of coagulation after AstraZeneca vaccination depend on genetic factors, underlying disease, lifestyle, medications, factor V Leiden (risk of blood clots). According to the clinical symptom guidelines, the above events are rare and usually appear 4 to 28 days after Covid-19 vaccination with persistent, severe headache; localized neurological symptoms; convulsions, blurred vision, or double vision; difficulty breathing or chest pain; stomachache; pain, swelling of the lower extremities. In particular, patients rarely present with bleeding, skin hemorrhage, or internal bleeding. The Ministry of Health believes that lower level medical facilities can completely handle the clotting phenomenon According to the Ministry of Health, at commune, ward, district or equivalent health centers of grade IV, people should be monitored after vaccination. If at least 1 of the above clinical symptoms appears, it is necessary to transfer the person after Covid-19 vaccination to a higher level or seek emergency treatment if any. In the case of the district hospital, district or equivalent grade III, after injection appears one of the above symptoms need to carry out the following tests: Count the platelet count; basic coagulation tests; quantitative D-dinmer assay; Ultrasound, X-ray exploration … In case of after injection, symptoms need to be transferred to higher level for treatment. At the provincial, city or equivalent level II health facilities, basic tests are needed to count platelet count, and basic coagulation test; quantitative D-dimer assay; imaging tests to assess thrombosis and bleeding; perform other exploration if available. In cases beyond the capacity of diagnosis and treatment, it is necessary to consult a higher level specialist. At the central grassroots level or equivalent grade I, the special class will take in people after vaccination with severe complications transferred by the levels, and carry out all necessary investigations for diagnosis and treatment according to the diagnosis and treatment guidelines of the Ministry of Health; Consult experts as needed. According to the Ministry of Health, by the morning of April 23, an additional 20,203 people were vaccinated against Covid-19 of AstraZeneca. Thus, from March 8 to now, a total of 128,610 people have been vaccinated against Covid-19 of AstraZeneca phase 1 and phase 2 in 28 provinces and cities and have not recorded any cases of blood clots later. injection.
You must log in to post a comment.